WuXi partners up for J&J, Pharmacyclics' Imbruvica; Almac expands ADC offering;

> WuXi PharmaTech ($WX) has inked a supply deal with Pharmacyclics ($PCYC) covering the just-approved Imbruvica, a potential blockbuster cancer drug co-developed with Johnson & Johnson ($JNJ). More

> CMO Almac says it has a novel approach to antibody-drug conjugate development, and the company has convinced Pfizer ($PFE) of the merits of its technology. Article

> Clinical IT outfit Datatrak landed $3 million in revenue last quarter, a 21% increase over the same period last year. Results